Veru Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

VeruDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -44.3% zurückgegangen, während in der Branche Personal Products die Gewinne wachsen. Die Umsätze sind rückläufig mit einer durchschnittlichen Rate von 14.2% pro Jahr.

Wichtige Informationen

-44.3%

Wachstumsrate der Gewinne

-39.0%

EPS-Wachstumsrate

Personal Products Wachstum der Industrie	20.9%
Wachstumsrate der Einnahmen	-14.2%
Eigenkapitalrendite	-99.4%
Netto-Marge	-265.4%
Letzte Ertragsaktualisierung	30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Is Veru (NASDAQ:VERU) A Risky Investment?

Aug 07

What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You

Jul 17

Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

May 31

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Jan 09

Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

Aug 16

Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Apr 17

Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

Feb 14

Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer

Aug 03

Aufschlüsselung der Einnahmen und Ausgaben

Wie Veru Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqCM:VERU Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 24	14	-37	30	40
31 Mar 24	13	-39	34	17
31 Dec 23	16	-63	51	32
30 Sep 23	16	-93	52	51
30 Jun 23	15	-126	63	48
31 Mar 23	21	-136	63	84
31 Dec 22	28	-116	46	81
30 Sep 22	39	-84	43	71
30 Jun 22	52	-47	31	52
31 Mar 22	60	-28	26	45
31 Dec 21	61	-16	23	37
30 Sep 21	61	7	21	33
30 Jun 21	57	0	19	28
31 Mar 21	50	0	17	21
31 Dec 20	47	2	16	17
30 Sep 20	43	-19	15	17
30 Jun 20	40	-10	15	17
31 Mar 20	39	-10	15	18
31 Dec 19	36	-13	15	17
30 Sep 19	32	-12	14	14
30 Jun 19	28	-17	15	13
31 Mar 19	24	-22	15	12
31 Dec 18	20	-22	15	11
30 Sep 18	16	-24	15	11
30 Jun 18	14	-21	14	9
31 Mar 18	13	-14	13	6
31 Dec 17	13	-11	12	5
30 Sep 17	14	-9	12	3
30 Jun 17	14	-6	10	2
31 Mar 17	15	-4	8	1
31 Dec 16	17	-3	8	0
30 Sep 16	22	0	9	0
30 Jun 16	26	3	10	0
31 Mar 16	28	3	12	0
31 Dec 15	34	5	13	0
30 Sep 15	33	4	12	0
30 Jun 15	31	3	12	0
31 Mar 15	31	3	11	0
31 Dec 14	24	2	9	0
30 Sep 14	24	2	9	0
30 Jun 14	24	10	6	0
31 Mar 14	23	9	7	0
31 Dec 13	28	12	7	0

Qualität der Erträge: VERU ist derzeit unrentabel.

Wachsende Gewinnspanne: VERU ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: VERU ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 44.3% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von VERU verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: VERU ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Personal Products (-5.2%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: VERU hat eine negative Eigenkapitalrendite (-99.42%), da es derzeit unrentabel ist.

Veru Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Veru Inc. to Report Q3, 2024 Results on Aug 08, 2024

Veru Inc. to Report Q2, 2024 Results on May 08, 2024

Veru Inc. to Report Q1, 2024 Results on Feb 08, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

New minor risk - Market cap size

Veru Inc. Announces Meta-Analysis of Body Composition Data from Older Patients with Obesity Which Supports Potential for Enobosarm to Optimize Weight Loss At Obesityweek

Veru Receives Notification from The Nasdaq Stock Market

Consensus EPS estimates fall by 12%, revenue upgraded

Price target increased by 16% to US$4.00

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Veru (NASDAQ:VERU) A Risky Investment?

Veru Inc. to Report Q3, 2024 Results on Aug 08, 2024

What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You

New major risk - Financial position

Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference

Chairman recently sold US$247k worth of stock

Consensus revenue estimates increase by 65%, EPS downgraded

High number of new and inexperienced directors

Veru Inc. to Report Q2, 2024 Results on May 08, 2024

Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board

Veru Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss

Veru Inc. announced delayed 10-Q filing

Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study

Veru Receives Non-Compliance Notice From Nasdaq

Veru Inc., Annual General Meeting, Mar 26, 2024

Veru Inc. to Report Q1, 2024 Results on Feb 08, 2024

Consensus revenue estimates decrease by 32%, EPS upgraded

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss

New major risk - Shareholder dilution

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication

Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy

Consensus revenue estimates decrease by 44%, EPS upgraded

Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

New major risk - Financial position

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

Veru Inc. to Report Q3, 2023 Results on Aug 10, 2023

High number of new and inexperienced directors

Veru Inc.(NasdaqCM:VERU) dropped from Russell 2000 Dynamic Index

Veru Announces Executive Appointments

Consensus revenue estimates increase by 12%

Veru Inc. announced that it expects to receive $100 million in funding from Lincoln Park Capital, LLC

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Veru Inc., Annual General Meeting, Mar 28, 2023

Veru Inc. to Report Q1, 2023 Results on Feb 09, 2023

Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Veru Inc

Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?

Veru Inc. Appoints David D. Ho as Chairman of Its Scientific Advisory Board

Consensus revenue estimates fall by 60%

Wolf Haldenstein Adler Freeman & Herz LLP Announces Securities Class Action Lawsuit Against Veru Inc

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$25.60

Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Price target decreased to US$25.60

Veru Inc. Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Veru Inc. Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Veru Inc.: Safer Bet Is To Wait For The AdComm Verdict

Veru Inc. to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?

Veru FDA AdCom meeting for COVID-19 therapy postponed